PHATHealthcare · BiotechnologyThe 11 Wall Street analysts covering Phathom Pharmaceuticals, Inc. hold a median 12-month price target of $22 — +278.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Phathom Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Momentum (24): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PHAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +278.5% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | Leerink Partners | Initiates | Market Perform | $10 |
| 17 Aug 2026 | Barclays | Maintains | Overweight | $18 → $14 |
| 17 Aug 2026 | Barclays | Maintains | Overweight | — |
| 31 July 2026 | Guggenheim | Maintains | Buy | $25 → $22 |
| 31 July 2026 | Guggenheim | Maintains | Buy | — |
| 31 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $26 |
| 31 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 July 2026 | Needham | Maintains | Buy | — |
| 30 July 2026 | Needham | Maintains | Buy | $28 → $22 |
| 17 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $26 |
| 27 Mar 2026 | Barclays | Upgrade | Overweight | — |
| 27 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Equal-Weight | — |
| 31 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 June 2025 | Craig-Hallum | Maintains | Buy | — |
| 9 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 June 2025 | Needham | Maintains | Buy | — |
| 2 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 2 May 2025 | Goldman Sachs | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PHAT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Phathom Pharmaceuticals, Inc. returned −57.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 56% of US stocks
Cheaper than 95% of US stocks
Cheaper than 93% of US stocks
Higher than 90% of US stocks
Higher than 82% of US stocks
Higher than 90% of US stocks
Higher than 31% of US stocks
Higher than 13% of US stocks
Higher than 93% of US stocks
Higher than 32% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Phathom Pharmaceuticals, Inc. has a market value of $465.8M and an enterprise value of $851.7M.
Revenue in the twelve months to 30 June 2026: $239.7M. The latest quarter grew 71.1% year on year.
Net income over the same four quarters: −$99.1M, a −41.3% net margin.
Diluted earnings per share, trailing twelve months: $−1.28.
Free cash flow in the twelve months to 30 June 2026: −$36.9M.
Trailing P/E: −1.9×; forward P/E: 5.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Phathom Pharmaceuticals, Inc. employs 371 people — $646K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Phathom Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Phathom Pharmaceuticals said members of its management team are scheduled to participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026, including a fireside chat at 3:00 p.m.
Why it matters — The conference appearance gives PHAT watchers a scheduled opportunity to hear from the company’s management team.
Phathom Pharmaceuticals announced that eligible commercially insured patients may now pay as little as $0 for VOQUEZNA (vonoprazan) tablets when obtained exclusively through BlinkRx.
Why it matters — The announcement concerns access and potential out-of-pocket costs for a Phathom product.
Phathom Pharmaceuticals reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation. The company said it continued efforts to expand access to its GERD treatment VOQUEZNA.
Why it matters — The update highlights revenue growth and progress toward positive operating results as Phathom works to expand access to VOQUEZNA.
Seeking Alpha published a transcript of Phathom Pharmaceuticals’ Q3 2026 earnings call. The provided excerpt contains no further details about the discussion.
Why it matters — The transcript may provide PHAT watchers with management’s commentary, but no specific business updates are included in the supplied text.
Phathom Pharmaceuticals reported quarterly earnings of $0.04 per share, below the Zacks consensus estimate of $0.07. The company reported a loss of $0.15 per share a year earlier.
Why it matters — PHAT watchers may note that quarterly earnings fell short of the consensus estimate, despite improving from the prior-year loss.
The 11 Wall Street analysts covering Phathom Pharmaceuticals, Inc. have a median 12-month price target of $22, with estimates ranging from $7.5 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Phathom Pharmaceuticals, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phathom Pharmaceuticals, Inc. 82 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Phathom Pharmaceuticals, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +278.5% from the last close, and Ticker Nerd's factor model ranks Phathom Pharmaceuticals, Inc. 82 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Phathom Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.5 to $29 over the next 12 months.
Phathom Pharmaceuticals, Inc. returned -57.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Phathom Pharmaceuticals to Participate in November Investor Conferences". Phathom Pharmaceuticals said members of its management team are scheduled to participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026, including a fireside chat at 3:00 p.m.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s commercial portfolio centers on vonoprazan-based therapies, including VOQUEZNA for the relief of heartburn associated with non-erosive and erosive GERD and the healing and maintenance of erosive GERD in adults. It also markets VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for the treatment of Helicobacter pylori infection in adults. Phathom Pharmaceuticals operates as a specialist in acid-related GI disorders, combining research, product development, and commercialization to address conditions that affect the digestive system.
CEO Mr. Steven L. Basta M.B.A. · 371 employees · United States · https://www.phathompharma.com
